Apogee Therapeutics Acquired by AbbVie at 49% Premium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: Yahoo Finance
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 90.380
Low
83.00
Averages
105.67
High
137.00
Current: 90.380
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apogee Therapeutics Acquired by AbbVie at 49% Premium
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
See More
AbbVie Acquires Apogee for Approximately $10.9 Billion
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, which underscores AbbVie's robust presence and expansion strategy in the pharmaceutical market.
- Shareholder Value Enhancement: The agreed purchase price represents a nearly 47% premium over Apogee's previous closing price, which is expected to garner support from Apogee shareholders, further solidifying AbbVie's market position in the biopharmaceutical sector.
- Drug Development Potential: Apogee's leading drug, zumilokibart, has shown promising results in clinical trials for eczema and asthma, with its long-lasting effects providing a competitive edge in the market, likely contributing to significant future revenues for AbbVie.
- Financial Impact Analysis: Although the acquisition is projected to negatively impact AbbVie's non-GAAP EPS in the short term, analysts anticipate that the earnings per share will remain strong at $14.24 and $16.25 over the next two years, reflecting market confidence in AbbVie's stock.
See More
AbbVie Acquires Apogee for $10.9 Billion to Enhance Immunology Portfolio
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, paying $135.11 per share in cash, which represents a nearly 47% premium over Apogee's previous closing price, indicating strong market confidence in the deal.
- Drug Development Potential: Apogee's leading drug candidate, zumilokibart, is currently in Phase 2 trials for moderate-to-severe atopic dermatitis, with long-lasting effects that require administration only every three to six months, positioning it as a strong competitor against existing treatments if approved.
- Financial Impact Analysis: Although the acquisition is expected to reduce AbbVie's non-GAAP EPS by $0.14 in 2023 and $0.46 in 2027, analysts project EPS to reach $14.24 and $16.25 in the next two years, reflecting the long-term value of the acquisition.
- Strategic Growth Outlook: By acquiring Apogee, AbbVie further solidifies its position in the biopharmaceutical sector, with the transaction expected to close in Q3 2023, enhancing its competitiveness in the treatment of immune and inflammatory diseases and driving sustained growth for the company.
See More
Apogee Therapeutics Shares Surge 46.66% on AbbVie Acquisition Offer
- Significant Price Surge: Apogee Therapeutics' stock surged 46.66% to $132.55, primarily driven by AbbVie's cash acquisition offer of $135.11 per share, indicating strong market optimism regarding the deal's success.
- Volume Spike: Trading volume reached 61.7 million shares, approximately 3,064% above the three-month average of 1.9 million shares, reflecting heightened investor interest and engagement in the stock.
- Positive Market Sentiment: The market largely believes that AbbVie's $10.9 billion acquisition proposal will close successfully in Q3, with shares currently trading just 2% below the offer price, showcasing investor confidence in Apogee's future prospects.
- Strategic Implications: This acquisition will inject new momentum into AbbVie's immunology pipeline, as Apogee's ongoing clinical trials for asthma, atopic dermatitis, and eosinophilic esophagitis could significantly enhance AbbVie's drug portfolio moving forward.
See More
Mixed Market Close: Tech Stocks Decline Amid Leadership Changes
- Tech Stock Decline: Alphabet's stock fell over 5% following the announcement of Google DeepMind VP Jumper's departure, leading to a broader decline in major tech stocks, which may heighten investor uncertainty regarding the tech sector's future performance.
- Oil Price Volatility: Oil prices initially surged over 2% after Iran threatened to close the Strait of Hormuz, but later retreated due to reported progress in peace talks with the US, highlighting the direct impact of geopolitical tensions on market dynamics and prompting investors to reassess energy sector risks.
- Market Expectation Shift: The market is currently pricing in a 39% chance of a 25 basis point rate hike at the upcoming FOMC meeting, reflecting a cautious investor sentiment towards future monetary policy, which could influence market liquidity and investment strategies.
- Overseas Market Performance: European and Asian stock markets closed higher, with the Euro Stoxx 50 and Japan's Nikkei 225 rising by 0.29% and 1.55% respectively, indicating a divergence in global market trends that may provide some support for the US market.
See More
Apogee Therapeutics Shares Surge 46.66% Following AbbVie Acquisition Offer
- Acquisition Proposal Surge: Apogee Therapeutics' stock surged 46.66% to $132.55 following AbbVie's cash acquisition offer of $135.11 per share, indicating strong market optimism about the deal potentially closing in the near term.
- Volume Spike: Trading volume reached 61 million shares, approximately 3,064% above the three-month average of 1.9 million shares, reflecting heightened investor interest and engagement in Apogee's future prospects.
- Strong IPO Performance: Since its IPO in 2023, Apogee Therapeutics has seen a remarkable 524% increase in stock price, showcasing robust market performance and investor confidence in the biopharmaceutical sector.
- Significant Pipeline Potential: AbbVie's acquisition would bolster its immunology pipeline, as Apogee has ongoing clinical trials for asthma, atopic dermatitis, and eosinophilic esophagitis, which could strategically replace AbbVie's existing drugs in the long term.
See More
Apogee Therapeutics Acquired by AbbVie at 49% Premium
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
See More
AbbVie Acquires Apogee for Approximately $10.9 Billion
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, which underscores AbbVie's robust presence and expansion strategy in the pharmaceutical market.
- Shareholder Value Enhancement: The agreed purchase price represents a nearly 47% premium over Apogee's previous closing price, which is expected to garner support from Apogee shareholders, further solidifying AbbVie's market position in the biopharmaceutical sector.
- Drug Development Potential: Apogee's leading drug, zumilokibart, has shown promising results in clinical trials for eczema and asthma, with its long-lasting effects providing a competitive edge in the market, likely contributing to significant future revenues for AbbVie.
- Financial Impact Analysis: Although the acquisition is projected to negatively impact AbbVie's non-GAAP EPS in the short term, analysts anticipate that the earnings per share will remain strong at $14.24 and $16.25 over the next two years, reflecting market confidence in AbbVie's stock.
See More
AbbVie Acquires Apogee for $10.9 Billion to Enhance Immunology Portfolio
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, paying $135.11 per share in cash, which represents a nearly 47% premium over Apogee's previous closing price, indicating strong market confidence in the deal.
- Drug Development Potential: Apogee's leading drug candidate, zumilokibart, is currently in Phase 2 trials for moderate-to-severe atopic dermatitis, with long-lasting effects that require administration only every three to six months, positioning it as a strong competitor against existing treatments if approved.
- Financial Impact Analysis: Although the acquisition is expected to reduce AbbVie's non-GAAP EPS by $0.14 in 2023 and $0.46 in 2027, analysts project EPS to reach $14.24 and $16.25 in the next two years, reflecting the long-term value of the acquisition.
- Strategic Growth Outlook: By acquiring Apogee, AbbVie further solidifies its position in the biopharmaceutical sector, with the transaction expected to close in Q3 2023, enhancing its competitiveness in the treatment of immune and inflammatory diseases and driving sustained growth for the company.
See More
Apogee Therapeutics Shares Surge 46.66% on AbbVie Acquisition Offer
- Significant Price Surge: Apogee Therapeutics' stock surged 46.66% to $132.55, primarily driven by AbbVie's cash acquisition offer of $135.11 per share, indicating strong market optimism regarding the deal's success.
- Volume Spike: Trading volume reached 61.7 million shares, approximately 3,064% above the three-month average of 1.9 million shares, reflecting heightened investor interest and engagement in the stock.
- Positive Market Sentiment: The market largely believes that AbbVie's $10.9 billion acquisition proposal will close successfully in Q3, with shares currently trading just 2% below the offer price, showcasing investor confidence in Apogee's future prospects.
- Strategic Implications: This acquisition will inject new momentum into AbbVie's immunology pipeline, as Apogee's ongoing clinical trials for asthma, atopic dermatitis, and eosinophilic esophagitis could significantly enhance AbbVie's drug portfolio moving forward.
See More
Mixed Market Close: Tech Stocks Decline Amid Leadership Changes
- Tech Stock Decline: Alphabet's stock fell over 5% following the announcement of Google DeepMind VP Jumper's departure, leading to a broader decline in major tech stocks, which may heighten investor uncertainty regarding the tech sector's future performance.
- Oil Price Volatility: Oil prices initially surged over 2% after Iran threatened to close the Strait of Hormuz, but later retreated due to reported progress in peace talks with the US, highlighting the direct impact of geopolitical tensions on market dynamics and prompting investors to reassess energy sector risks.
- Market Expectation Shift: The market is currently pricing in a 39% chance of a 25 basis point rate hike at the upcoming FOMC meeting, reflecting a cautious investor sentiment towards future monetary policy, which could influence market liquidity and investment strategies.
- Overseas Market Performance: European and Asian stock markets closed higher, with the Euro Stoxx 50 and Japan's Nikkei 225 rising by 0.29% and 1.55% respectively, indicating a divergence in global market trends that may provide some support for the US market.
See More
Apogee Therapeutics Shares Surge 46.66% Following AbbVie Acquisition Offer
- Acquisition Proposal Surge: Apogee Therapeutics' stock surged 46.66% to $132.55 following AbbVie's cash acquisition offer of $135.11 per share, indicating strong market optimism about the deal potentially closing in the near term.
- Volume Spike: Trading volume reached 61 million shares, approximately 3,064% above the three-month average of 1.9 million shares, reflecting heightened investor interest and engagement in Apogee's future prospects.
- Strong IPO Performance: Since its IPO in 2023, Apogee Therapeutics has seen a remarkable 524% increase in stock price, showcasing robust market performance and investor confidence in the biopharmaceutical sector.
- Significant Pipeline Potential: AbbVie's acquisition would bolster its immunology pipeline, as Apogee has ongoing clinical trials for asthma, atopic dermatitis, and eosinophilic esophagitis, which could strategically replace AbbVie's existing drugs in the long term.
See More
